A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction, according to a new paper published in the Journal of the Endocrine Society. The therapies, known as Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), present an encouraging approach to treating alcohol and other substance use disorders. “Early...
GLP-1 Agonists and Muscle Loss: A Hidden Risk for Older Adults
As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — such as semaglutide (Ozempic, Wegovy) — gain traction for treating diabetes and promoting weight loss, a new concern is emerging: Are older adults at risk of losing too much muscle? An editorial in Annals of Internal Medicine warns that these popular drugs may exacerbate sarcopenia — the...
Tightrope: Obesity Management in Women During Reproductive Years
As part of the ENDO 2025 session, “Obesity Management Across the Lifespan: Special Considerations,” Lisa Morselli, MD, PhD, talks about the unique challenges in obesity management in women during their reproductive years. On Tuesday, July 15, ENDO 2025 here in San Francisco will feature a session titled, “Obesity Management Across the Lifespan: Special Considerations.” As...Anti-Obesity Medications Can Normalize Testosterone Levels in Men
Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type 2 diabetes, according to a new study being presented Monday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. Testosterone not only plays a critical role in the body when it comes to male sexual...
Intermittent Energy Restriction May Improve Outcomes in People with Obesity and Type 2 Diabetes
Intermittent energy restriction, time-restricted eating and continuous energy restriction can all improve blood sugar levels and body weight in people with obesity and type 2 diabetes, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. “This study is the first to compare the effects of...
Obesity-Associated Cancers Tripled Nationwide Over Past Two Decades
Cancer deaths linked to obesity have tripled in the United States over the past two decades, according to a study being presented Sunday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif. The study, which examined more than 33,000 deaths from obesity-associated cancers, revealed sharp increases in cancer deaths, especially among women,...
New Study Questions BMI Accuracy in Childhood Obesity Screening
A new study from the Avon Longitudinal Study of Parents and Children (ALSPAC) is challenging long-held assumptions about how we measure overweight and obesity in children. According to findings published in Obesity and Endocrinology in January 2025, body mass index (BMI) — the most commonly used tool for assessing weight status — may dramatically overestimate...
The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate. The legislation will ensure that Medicare and Medicaid beneficiaries have access to effective anti-obesity medications. Medicare coverage of anti-obesity medications is currently prohibited under law. Access to these medications would benefit millions of Americans. More than...
